10% Owner Carmen Chang Makes Substantial $15M Open Market Purchase Post-IPO
Summary
10% owner Carmen Chang, through affiliated entities, made a significant $15 million open market purchase of SpyGlass Pharma common stock at the IPO price, alongside the conversion of over 6.4 million preferred shares to common stock following the company's recent IPO.
Key Events
-
Substantial Open Market Purchase
10% owner Carmen Chang acquired $15,000,000 worth of common stock on the open market.
-
IPO-Related Transaction
The purchase was made at the IPO price of $16.00 per share on February 9, 2026, the day the IPO closed.
-
Preferred Stock Conversion
Over 6.4 million shares of preferred stock automatically converted to common stock as part of the IPO process.
-
Post-IPO Insider Confidence
This transaction contributes to a cluster of significant insider buying activity observed immediately after SpyGlass Pharma's IPO, following other director purchases.
Analysis
This Form 4 filing reveals a substantial vote of confidence from a major 10% owner, Carmen Chang, who acquired $15 million worth of common stock on the open market at the IPO price of $16.00 per share. This purchase, representing a notable portion of the company's market capitalization, occurred on the same day SpyGlass Pharma closed its initial public offering. The filing also details the automatic conversion of over 6.4 million shares of preferred stock into common stock, a mechanical event tied to the IPO. This significant insider buying, coupled with other recent director purchases, signals strong conviction from key stakeholders immediately following the company's public debut.
At the time of this filing, SGP was trading at $26.18 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $835.4M. The 52-week trading range was $24.71 to $28.93. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.